Apol6, also known as Apolipoprotein L6, is a gene with diverse functions. In adipose tissue, it associates with lipid droplets and impacts adipocyte lipolysis by disrupting the Perilipin1-HSL interaction [1]. It is also involved in regulating the differentiation of intramuscular preadipocytes in goats [3]. In addition, Apol6 has potential connections to cancer-related processes, such as predicting immunotherapy efficacy in bladder cancer through ferroptosis [2], and being involved in radiosensitivity-related processes in rectal cancer [4].

In adipocytes, ApoL6 knockdown results in smaller lipid droplets with lower TAG content, while overexpression leads to larger lipid droplets with higher TAG content. ApoL6 ablation in mice decreases white adipose tissue mass, protecting them from diet-induced obesity, indicating its role in obesity-related mechanisms [1]. In bladder cancer, Apol6 was identified as a biomarker predicting the efficacy of immune checkpoint inhibitors, and it mediates immunotherapy efficacy by ferroptosis [2].

In conclusion, Apol6 plays crucial roles in lipid metabolism in adipose tissue, potentially contributing to obesity-related conditions. In the cancer context, it shows promise as a biomarker for predicting immunotherapy efficacy in bladder cancer and is associated with rectal cancer radiosensitivity. The study of Apol6 using gene-knockout models in mice has provided valuable insights into its functions in these biological processes and disease conditions.